

CITATION REPORT

List of articles citing

Cardiovascular risk and sildenafil

DOI: 10.1016/s0002-9149(00)00895-x
American Journal of Cardiology, 2000, 86, 57F-61F.

Source: <https://exaly.com/paper-pdf/31523906/citation-report.pdf>

Version: 2024-04-26

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
73	Sexual activity and cardiac risk: the Princeton Conference. Introductory comments. <i>American Journal of Cardiology</i> , 2000 , 86, 3F-4F	3	
72	Sleep-disordered breathing and hypertension. <i>New England Journal of Medicine</i> , 2000 , 343, 967	59.2	14
71	A risk-benefit assessment of sildenafil in the treatment of erectile dysfunction. <i>Drug Safety</i> , 2001 , 24, 255-65	5.1	3
70	Disfunci3 sexual en la hipertensi3 y beneficios del tratamiento con sildenafilo. <i>Hipertension Y Riesgo Vascular</i> , 2001 , 18, 59-62	0.5	
69	Editor3 comment on: "Press release: further research supports Viagra safety profile". <i>BJU International</i> , 2001 , 87, 905-7; author reply 907-9	5.6	
68	Effect of sildenafil on blood pressure and arterial wave reflection in treated hypertensive men. <i>Journal of Human Hypertension</i> , 2001 , 15, 707-13	2.6	77
67	Cardiovascular safety in erectile dysfunction treatment. <i>British Journal of Diabetes and Vascular Disease</i> , 2002 , 2, 301-304		5
66	Sildenafil (Viagra) induces powerful cardioprotective effect via opening of mitochondrial K(ATP) channels in rabbits. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2002 , 283, H1263-9	5.2	218
65	Drugs acting on the cerebral and peripheral circulations. <i>Side Effects of Drugs Annual</i> , 2002 , 25, 236-239	0.2	
64	Fatal overdose with sildenafil citrate (Viagra): first report and review of the literature. <i>Human and Experimental Toxicology</i> , 2002 , 21, 623-9	3.4	21
63	Interactions of sildenafil with various coronary vasodilators in isolated porcine coronary artery. <i>European Journal of Pharmacology</i> , 2002 , 437, 155-63	5.3	17
62	Last performance with VIAGRA: post-mortem identification of sildenafil and its metabolites in biological specimens including hair sample. <i>Forensic Science International</i> , 2002 , 126, 71-6	2.6	36
61	Effects of phosphodiesterase 3,4,5 inhibitors on hepatocyte cAMP levels, glycogenolysis, gluconeogenesis and susceptibility to a mitochondrial toxin. <i>Molecular and Cellular Biochemistry</i> , 2003 , 252, 205-11	4.2	68
60	Sildenafil: a 4-year update in the treatment of 20 million erectile dysfunction patients. <i>Current Urology Reports</i> , 2003 , 4, 488-96	2.9	31
59	Effects of sildenafil citrate (Viagra) on hemodynamic parameters during exercise testing and occurrence of ventricular arrhythmias in patients with erectile dysfunction and cardiovascular disease. <i>European Urology</i> , 2003 , 43, 544-51	10.2	12
58	Sildenafil in patients with cardiovascular disease. <i>American Journal of Cardiology</i> , 2003 , 92, 26M-36M	3	32
57	Cardiovascular effects of tadalafil. <i>American Journal of Cardiology</i> , 2003 , 92, 37M-46M	3	98

56	1,7- and 2,7-naphthyridine derivatives as potent and highly specific PDE5 inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2003 , 13, 2341-5	2.9	25
55	Coronary artery flow reserve in diabetics with erectile dysfunction using sildenafil. <i>Cardiovascular Diabetology</i> , 2003 , 2, 8	8.7	5
54	Cardiovascular safety of sildenafil. <i>Drug Safety</i> , 2003 , 26, 453-60	5.1	14
53	4-Aryl-3-(hydroxyalkyl)quinolin-2-ones: novel maxi-K channel opening relaxants of corporal smooth muscle targeted for erectile dysfunction. <i>Journal of Medicinal Chemistry</i> , 2003 , 46, 2819-22	8.3	84
52	Therapeutic potential of phosphodiesterase 5 inhibition for cardiovascular disease. <i>Circulation</i> , 2003 , 108, 239-44	16.7	124
51	Erectile dysfunction and the cardiovascular patient: endothelial dysfunction is the common denominator. <i>British Heart Journal</i> , 2003 , 89, 251-3		307
50	Cyclic GMP phosphodiesterases and regulation of smooth muscle function. <i>Circulation Research</i> , 2003 , 93, 280-91	15.7	420
49	The pharmacology of nitric oxide in the peripheral nervous system of blood vessels. <i>Pharmacological Reviews</i> , 2003 , 55, 271-324	22.5	247
48	Treatment with sildenafil for the healing of refractory skin ulcerations in the antiphospholipid syndrome. <i>Lupus</i> , 2003 , 12, 133-5	2.6	31
47	Coronary heart disease in HIV-infected patients in the highly active antiretroviral treatment era. <i>Aids</i> , 2003 , 17 Suppl 1, S70-6	3.5	63
46	Erectile dysfunction in the cardiac patient. <i>Comprehensive Therapy</i> , 2004 , 30, 50-4		6
45	4-Aryl-3-(mercapto)quinolin-2-ones: novel maxi-K channel opening relaxants of corporal smooth muscle. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2004 , 14, 4479-82	2.9	28
44	Erectile dysfunction and cardiovascular disease. <i>Mayo Clinic Proceedings</i> , 2004 , 79, 782-94	6.4	14
43	Cardiovascular effects of the 3 phosphodiesterase-5 inhibitors approved for the treatment of erectile dysfunction. <i>Circulation</i> , 2004 , 110, 3149-55	16.7	143
42	Erectile Dysfunction and Cardiovascular Disease. <i>Mayo Clinic Proceedings</i> , 2004 , 79, 782-794	6.4	49
41	Effect of sildenafil on reperfusion function, infarct size, and cyclic nucleotide levels in the isolated rat heart model. <i>Cardiovascular Drugs and Therapy</i> , 2005 , 19, 23-31	3.9	40
40	Effect of sildenafil citrate on the cardiovascular system. <i>Brazilian Journal of Medical and Biological Research</i> , 2005 , 38, 1303-11	2.8	8
39	Disfunci3 sexual en la hipertensi3 arterial. <i>Hipertension</i> , 2005 , 22, 59-72		4

38	Disfunci3 sexual en la hipertensi3 arterial. <i>Hipertension Y Riesgo Vascular</i> , 2005 , 22, 59-72	0.5	0
37	Sildenafil-associated coronary thrombosis in a patient with angiographically normal coronary arteries: a case report with review of literature. <i>American Journal of Therapeutics</i> , 2006 , 13, 378-84	1	3
36	Effects of sildenafil citrate on defibrillation efficacy. <i>Journal of Cardiovascular Electrophysiology</i> , 2006 , 17, 292-5	2.7	14
35	Sudden cardiovascular death associated with sexual activity : A forensic autopsy study (1972-2004). <i>Forensic Science, Medicine, and Pathology</i> , 2006 , 2, 109-14	1.5	26
34	Sexuality and myocardial infarction. <i>American Journal of Nursing</i> , 2007 , 107, 49-52	0.6	17
33	Sildenafil citrate ingestion and prolonged priapism and tachycardia in a pediatric patient. <i>Clinical Toxicology</i> , 2007 , 45, 798-800	2.9	20
32	Sildenafil reduces L-NAME-induced severe hypertension and worsening of myocardial ischaemia-reperfusion damage in the rat. <i>British Journal of Pharmacology</i> , 2007 , 150, 567-76	8.6	42
31	Spontaneous coronary dissection following exertion: support for a hypothesis. <i>Internal Medicine Journal</i> , 2008 , 31, 501-502	1.6	
30	Management of high defibrillation threshold. <i>Expert Review of Cardiovascular Therapy</i> , 2008 , 6, 1237-48	2.5	8
29	Expression, activity, and function of phosphodiesterases in the mature and immature ductus arteriosus. <i>Pediatric Research</i> , 2008 , 64, 477-81	3.2	28
28	Phosphodiesterase 5 inhibitors: are they cardioprotective?. <i>Cardiovascular Research</i> , 2009 , 83, 204-12	9.9	29
27	Subarachnoid hemorrhage during sexual activity after sildenafil intake: an accidental association?. <i>American Journal of Forensic Medicine and Pathology</i> , 2011 , 32, 310-1	1	7
26	Sexual activity and ischemic heart disease. <i>Current Cardiology Reports</i> , 2014 , 16, 445	4.2	15
25	Cardiac safety profile of sildenafil: chronotropic, inotropic and coronary vasodilator effects in the canine isolated, blood-perfused heart preparations. <i>Journal of Toxicological Sciences</i> , 2016 , 41, 739-744	1.9	1
24	Update of the position paper on arterial hypertension and erectile dysfunction. <i>Journal of Hypertension</i> , 2020 , 38, 1220-1234	1.9	9
23	Cardiovascular Safety of Phosphodiesterase-5 Inhibitors. 2004 , 139-161		1
22	Spontaneous coronary dissection following exertion: support for a hypothesis. <i>Internal Medicine Journal</i> , 2001 , 31, 501-3	1.6	2
21	Transient renal effects of sildenafil in male kidney transplant recipients. <i>Transplantation</i> , 2001 , 72, 1331-38		10

20	Regulation and Function of Cyclic Nucleotide Phosphodiesterases in Vascular Smooth Muscle and Vascular Diseases. 2006,		1
19	Role of cGMP and cAMP in the hemodynamic response to intrathecal sildenafil administration. <i>Clinics</i> , 2011 , 66, 1407-12	2,3	3
18	Miscellaneous therapeutic and diagnostic agents. 2001 , 556-584		
17	Sildenafil citrate: a 5-year update on the worldwide treatment of 20 million men with erectile dysfunction. 2004 , 35-47		
16	Safety and Hemodynamic Effects of Sildenafil in Patients With Coronary Artery Disease. 2004 , 179-194		
15	Cardiovascular Safety of Sexual Activity and Phosphodiesterase Type 5 Inhibition. 2004 , 159-181		
14	Sexual Activity As a Trigger of Myocardial Infarction/Ischemia. 2004 , 251-260		
13	Risk of Heart Attack After Sexual Activity. 2004 , 279-288		
12	Cardiovascular Effects of Nonphosphodiesterase-5 Inhibitor Erectile Dysfunction Therapies. 2004 , 195-206		
11	Erectile Dysfunction Assessment and Management in Primary Care Practice. 2005 , 149-183		
10	Erectile Dysfunction. 2005 , 193-223		
9	Sildenafil. 2006 , 3133-3137		
8	DRUGS THAT ACT ON THE CEREBRAL AND PERIPHERAL ARTERIAL AND VENOUS CIRCULATIONS. 2009 , 431-448		
7	An unusual adverse effect of sildenafil citrate: acute myocardial infarction in a nitrate-free patient. <i>BMJ Case Reports</i> , 2012 , 2012,	0,9	4
6	Phosphodiesterase type V inhibitors. 2016 , 734-742		
5	Erectile Dysfunction as a Cardiovascular Risk Factor: Time to Step Up?. <i>Current Vascular Pharmacology</i> , 2021 , 19, 301-312	3,3	2
4	Cardiac Issues Related to Erectile Dysfunction. 2006 , 61-75		
3	Post-coital death in chronic sildenafil abuser. <i>Journal of Geriatric Cardiology</i> , 2020 , 17, 169-172		1,7

2 Assessment of Cardiovascular Risk for Noncardiac and Nonsurgical Activities. **2022,** 0

1 Sildenafil affects the human Kir2.1 and Kir2.2 channels at clinically relevant concentrations:
Inhibition potentiated by low Ba²⁺. 14, 1